Synthesis Capital

Costa Yiannoulis and Rosie Wardle serve as Managing Partner and Partner respectively, and as co-founders they make all investment decisions. Both previously worked at CPT Capital, where they sourced and managed early bets on Beyond Meat, Impossible Foods, and Perfect Day (per public record and Form ADV filings). No external investment committee is disclosed.

Synthesis Capital is a separate entity founded in 2020 by two former CPT Capital investment professionals, Costa Yiannoulis and Rosie Wardle. CPT Capital, the family office of Jeremy Coller, was an early institutional backer of alternative proteins and the prior professional home for Synthesis's founding team. There is no formal joint venture or shared ownership between the two firms.

The firm's mandate covers alternative proteins (plant-based, precision fermentation, and cellular agriculture) as well as the enabling infrastructure — including bioreactors, feedstock engineering, and bioprocess optimization — that determines whether these technologies can scale to cost parity. It does not invest in conventional agriculture, food distribution, or restaurant tech.

The founding team's decade-plus tenure in food-tech venture, dating to CPT Capital's earliest investments in the sector, gives Synthesis access to scientist-founders and university spinouts before generalist venture firms enter competitive processes. The firm also draws on relationships with sovereign wealth funds and family offices that co-invested alongside CPT Capital in prior fund cycles (per Bloomberg, 2023).

Synthesis invests primarily as a lead or co-lead in early-stage and growth rounds, with no publicly disclosed fund-of-funds program. Its debut vehicle accepted commitments from institutional LPs rather than operating a co-investment club for family offices or high-net-worth individuals. The firm has not announced a dedicated co-investment vehicle as of mid-2026.